Publicacions en col·laboració amb investigadors/es de Hospital Universitario Nuestra Señora de Candelaria (26)

2024

  1. Risk factors for progression in KDOQI stage 3 Chronic Kidney Disease (PROGRESER study)

    Nefrologia, Vol. 44, Núm. 5, pp. 689-699

2023

  1. Mineral and bone metabolism markers and mortality in diabetic patients on haemodialysis

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 38, Núm. 11, pp. 2589-2597

  2. Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction—a substudy of the DAPA-VO2 study

    Frontiers in Cardiovascular Medicine, Vol. 10

2022

  1. Silver jubilee: 25 years of the first demonstration of the direct effect of phosphate on the parathyroid cell

    Nefrologia, Vol. 42, Núm. 6, pp. 645-655

2021

  1. Optimizing the timing of nephrology referral for patients with diabetic kidney disease

    Clinical Kidney Journal, Vol. 14, Núm. 1, pp. 5-8

  2. Setting up a cardiorenal clinic. Consensus document of the cardiorenal working groups of the Spanish Society of Cardiology and the Spanish Society of Nephrology

    REC: CardioClinics, Vol. 56, Núm. 4, pp. 284-295

  3. Urinary Dickkopf-3: A new biomarker for CKD progression and mortality

    Nephrology Dialysis Transplantation, Vol. 36, Núm. 12, pp. 2199-2207

2020

  1. Association of a single nucleotide polymorphism combination pattern of the Klotho gene with non-cardiovascular death in patients with chronic kidney disease

    Clinical Kidney Journal, Vol. 13, Núm. 6, pp. 1017-1024

  2. GLP-1 receptor agonists and diabetic kidney disease: A call of attention to nephrologists

    Journal of Clinical Medicine, Vol. 9, Núm. 4

  3. Prevalence of vertebral fractures and their prognostic significance in the survival in patients with chronic kidney disease stages 3-5 not on dialysis

    Journal of Clinical Medicine, Vol. 9, Núm. 5, pp. 1-11

  4. SGLT2 inhibitors for non-diabetic kidney disease: Drugs to treat CKD that also improve glycaemia

    Clinical Kidney Journal, Vol. 13, Núm. 5, pp. 728-733

  5. Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 35, Núm. 1, pp. i13-i23

2019

  1. Association of candidate gene polymorphisms with chronic kidney disease: Results of a case-control analysis in the NEFRONA cohort

    Frontiers in Genetics, Vol. 10, Núm. FEB

  2. Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: What was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?

    Clinical Kidney Journal, Vol. 12, Núm. 3, pp. 313-321

  3. Will the new hypoglycaemic agents be effective on renal and cardiovascular protection in diabetes and renal diabetic disease?

    Nefrologia, Vol. 39, Núm. 1, pp. 3-10

2018

  1. Effects of pentoxifylline on soluble klotho concentrations and renal tubular cell expression in diabetic kidney disease

    Diabetes Care, Vol. 41, Núm. 8, pp. 1817-1820

2017

  1. ERBP guideline on management of patients with diabetes and chronic kidney disease stage 3B or higher. Metformin for all?

    Nefrologia, Vol. 37, Núm. 6, pp. 567-571

  2. Factors influencing pathological ankle-brachial index values along the chronic kidney disease spectrum: The NEFRONA study

    Nephrology Dialysis Transplantation, Vol. 32, Núm. 3, pp. 513-520

2015

  1. Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease

    Nephrology Dialysis Transplantation, Vol. 30, Núm. 7, pp. 1176-1185

  2. Nephroprotection by hypoglycemic agents: Do we have supporting data?

    Journal of Clinical Medicine, Vol. 4, Núm. 10, pp. 1866-1889